540787-75-5 Usage
General Description
(3S)-1-(2-Aminoethyl)-3-pyrrolidinol, also known as (S)-(-)-1-(2-Aminoethyl)pyrrolidin-3-ol, is a chemical compound with the molecular formula C6H14N2O. It is a chiral compound with a three-carbon straight chain and a pyrrolidine ring. (3S)-1-(2-Aminoethyl)-3-pyrrolidinol is commonly used as a chiral auxiliary in organic synthesis and as a building block for the synthesis of various pharmaceuticals and biologically active compounds. It is also used in the preparation of chiral ligands for asymmetric catalysis and in the development of new drug entities. Additionally, (3S)-1-(2-Aminoethyl)-3-pyrrolidinol has potential applications in the fields of medicine, agriculture, and materials science due to its unique structure and properties.
Check Digit Verification of cas no
The CAS Registry Mumber 540787-75-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,4,0,7,8 and 7 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 540787-75:
(8*5)+(7*4)+(6*0)+(5*7)+(4*8)+(3*7)+(2*7)+(1*5)=175
175 % 10 = 5
So 540787-75-5 is a valid CAS Registry Number.
InChI:InChI=1/C6H14N2O/c7-2-4-8-3-1-6(9)5-8/h6,9H,1-5,7H2/t6-/m0/s1
540787-75-5Relevant articles and documents
SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS
-
Paragraph 1214 - 1216, (2015/02/05)
The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.
SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: Taming hERG
Su, Jing,McKittrick, Brian A.,Tang, Haiqun,Burnett, Duane A.,Clader, John W.,Greenlee, William J.,Hawes, Brian E.,O'Neill, Kim,Spar, Brian,Weig, Blair,Kowalski, Timothy,Sorota, Steve,Li, Cheng,Liu, Tongtong
, p. 5369 - 5385 (2008/03/14)
To improve the ex vivo potency of MCH inhibitor 1a and to address its hERG liability, a structure-activity study was carried out, focusing on three regions of the lead structure. Introduction of new side chains with basic nitrogen improved in vitro and ex
